An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women

Trial Profile

An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Medroxyprogesterone (Primary)
  • Indications HIV-1 infections; Pregnancy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Sep 2011 Additional location [Puerto Rico, USA] identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top